Brokerages Set Agenus Inc. (NASDAQ:AGEN) PT at $8.75

Agenus Inc. (NASDAQ:AGEN) has been assigned a consensus recommendation of “Hold” from the six research firms that are presently covering the company, Marketbeat Ratings reports. Five analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $8.75.

Several brokerages have recently commented on AGEN. StockNews.com upgraded shares of Agenus from a “sell” rating to a “hold” rating in a research note on Friday, March 21st. Robert W. Baird decreased their price objective on shares of Agenus from $6.00 to $3.00 and set a “neutral” rating on the stock in a research note on Wednesday, March 12th. Finally, HC Wainwright reiterated a “neutral” rating on shares of Agenus in a research note on Tuesday, March 18th.

Agenus Trading Up 6.3 %

AGEN opened at $1.60 on Wednesday. The stock has a market cap of $40.49 million, a PE ratio of -0.14 and a beta of 1.23. Agenus has a 1 year low of $1.44 and a 1 year high of $19.69. The stock’s 50 day simple moving average is $2.76 and its 200-day simple moving average is $3.47.

Agenus (NASDAQ:AGEN) last announced its quarterly earnings results on Tuesday, March 11th. The biotechnology company reported ($2.04) EPS for the quarter, topping analysts’ consensus estimates of ($2.36) by $0.32. The business had revenue of $26.84 million for the quarter, compared to the consensus estimate of $30.09 million. Equities analysts forecast that Agenus will post -12.55 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Agenus

Large investors have recently modified their holdings of the stock. B. Riley Financial Inc. acquired a new stake in shares of Agenus in the fourth quarter valued at approximately $2,074,000. Gilead Sciences Inc. acquired a new stake in shares of Agenus in the 4th quarter valued at $635,000. Walleye Capital LLC bought a new stake in shares of Agenus during the third quarter worth $1,003,000. Jane Street Group LLC lifted its stake in shares of Agenus by 97.6% during the fourth quarter. Jane Street Group LLC now owns 105,705 shares of the biotechnology company’s stock valued at $290,000 after acquiring an additional 52,215 shares during the period. Finally, Deutsche Bank AG boosted its holdings in Agenus by 538.4% in the fourth quarter. Deutsche Bank AG now owns 61,144 shares of the biotechnology company’s stock valued at $168,000 after acquiring an additional 51,566 shares during the last quarter. 61.46% of the stock is currently owned by institutional investors and hedge funds.

Agenus Company Profile

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.